Hematologist
CION Cancer Clinics
High-risk smouldering myeloma: should you treat or watch? | CION Cancer Clinics
For high-risk smouldering myeloma, both early treatment and close watching are reasonable choices. Studies show early treatment can delay active myeloma in some people, but it brings side effects, cost and visits while you feel well, and its long-term benefit is still being studied. This page explains what high risk means, how the options compare, and what to ask your haematologist. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Should high-risk smouldering myeloma be treated or watched?
- What makes smouldering myeloma "high risk"?
- What are the options, and who does each suit?
- How do treating and watching compare?
- How is the decision usually made?
- What do families often assume about early treatment?
- What can this page not tell you?
- Common questions about high-risk smouldering myeloma
The short answer
Should high-risk smouldering myeloma be treated or watched?
There is no single right answer. For some people at high risk, early treatment can delay the move to active myeloma, and some haematologists now offer it. Many others choose close watching, and both are reasonable choices made with a haematologist.
Why this is a real decision
Studies have shown that early treatment can hold off active myeloma for longer in people at high risk. What is less settled is how much that changes things over a whole lifetime, and whether it is better than starting treatment promptly when the first sign of active disease appears. Treatment also brings side effects, cost and regular hospital visits while you still feel well.
Who this decision is for
This page is for people already told they have high-risk smouldering myeloma. If your risk is lower, early treatment is not usually offered, and close follow-up is the standard plan. If you already have organ damage, the diagnosis is active myeloma, and treatment is a different conversation.
Who makes the choice
You do, with your haematologist and your family. A well-informed decision is not the same for everyone. It depends on your results, your health, your priorities and how you feel about taking medicine while symptom-free.
This page describes options in general. It is not a recommendation for or against treatment in your case.On your report
What makes smouldering myeloma "high risk"?
- A larger amount of M-protein
- A higher protein level in the blood points to a higher chance of progression.
- A strongly abnormal light chain ratio
- When one light chain type far outweighs the other, the risk rises.
- A higher share of plasma cells in the marrow
- More plasma cells in the bone marrow sample adds to the risk.
- High-risk genetic changes
- Some changes found in the marrow cells, reported from tests such as FISH, point to faster progression.
- A rising trend
- A protein level or haemoglobin that keeps moving in the wrong direction over several tests is also taken into account.
Not sure whether this applies to you?
Ask an oncologistThe choices
What are the options, and who does each suit?
There are three broad paths. Each one keeps you under close watch by a haematology team.
Close watching
Blood tests every few months and imaging when needed. Treatment starts promptly if signs of active myeloma appear. You agree in advance which results would trigger that step.
Often suits
- People who want to avoid side effects while well
- People with serious other illnesses
Early treatment
Medicines such as lenalidomide, sometimes with dexamethasone, or daratumumab have been studied for high-risk smouldering myeloma. Your haematologist sets any medicine and its schedule.
May not suit
- People at lower risk
- People who cannot manage regular visits
A clinical trial
Trials test newer approaches with close monitoring. Availability in India is limited, and eligibility rules are strict. Joining one may mean travel and extra visits, and you can leave a trial at any time.
Ask your haematologist which trials, if any, fit your results and where they are running.Side by side
How do treating and watching compare?
Early treatment
Close watching
May delay the move to active myeloma
Treatment starts when active disease appears
Side effects while you still feel well
No medicine side effects during the watch
Regular clinic visits and blood tests
Regular blood tests and imaging
Ongoing medicine cost
Lower cost until treatment is needed
Relies on keeping to the treatment plan
Relies on keeping every follow-up test
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Working it out together
How is the decision usually made?
-
Confirm the diagnosis and the risk
A bone marrow test, sensitive imaging of the bones and repeat blood tests make sure there is no hidden organ damage and that the high-risk label is accurate.
-
A team review
At CION, the haematology team presents your case at a tumour board, where specialists review your results together. The team can also help arrange tests that are done at partner centres.
-
An honest conversation
Your haematologist explains the options, the expected side effects, the visits involved and the uncertainty. Bring the family member who helps you decide. Ask for time to think if you need it; this decision is rarely urgent.
-
A plan with review points
Whichever path you choose, agree which results would change the plan and when it will be looked at again. You can revisit the choice later.
Commonly believed
What do families often assume about early treatment?
"Treating early will stop myeloma for good."
Early treatment can delay active myeloma in some people, but it is not a promise that myeloma will never develop. It is one way of managing risk, not a way of removing it.
"Choosing to watch means giving up."
Watching is an active plan with close tests. Treatment can start quickly if needed, and many haematologists consider it entirely reasonable.
"If one relative's doctor treated early, I should be treated too."
Risk and health differ from person to person. A choice that fitted someone else may not fit your results. Stories from other families are worth hearing, but your own reports should guide the decision.
"Once I start, I can never stop."
Early treatment is usually given for a planned period and reviewed along the way. Never stop or change a medicine on your own; talk to your haematologist first.
Being straight with you
What can this page not tell you?
It cannot tell you which choice is right for you, or how your condition will behave. Risk models describe groups of people, and some people labelled high risk stay stable for years.
Questions worth asking
Ask how sure your doctor is that you are high risk, and which results put you there. Ask what side effects to expect from the treatment being offered, how often you would visit, and roughly what it would cost. Ask what would happen if you chose to watch instead.
Cost and schemes
Medicine costs vary widely. Coverage under Aarogyasri, CGHS, ECHS, EHS, PM-JAY and cashless insurance depends on current scheme rules, which change. Check your entitlement before starting. Ask the team for a written estimate against your own cover.
If you are the son or daughter helping decide
Come to the appointment, and let your parent speak first about what matters to them. Some people value time without medicines. Others value doing everything possible early. Neither is wrong. Write the options down in plain words and read them back together at home before deciding.
Reference ranges differ between laboratories. A single result is always read alongside symptoms and repeat tests.Questions we are asked
Common questions about high-risk smouldering myeloma
Does early treatment help people live longer?
Studies show early treatment can delay active myeloma in some high-risk people. Whether it helps people live longer is still being studied, and results so far are not settled. Your haematologist can explain what the evidence does and does not show for someone with your results.
What side effects could early treatment cause?
It depends on the medicine. Tiredness, rashes, loose motions, lower blood counts, infections and a higher risk of blood clots are among the effects your team watches for. Ask for a written list for the specific treatment offered, and whom to call if a side effect appears.
Can I change my mind after choosing to watch?
Yes. The decision can be revisited at any follow-up visit, especially if your results change. Tell your haematologist if your view has shifted. Equally, if treatment has started and you are struggling, discuss it with your team rather than stopping on your own.
Is chemotherapy used for smouldering myeloma?
Traditional chemotherapy is not the usual approach. The medicines studied for high-risk smouldering myeloma work in other ways, for example on the immune system or directly on plasma cells. Your haematologist will explain how any medicine offered works and how it is given.
Will I need a stem cell transplant?
Transplant is not used for smouldering myeloma. It may be discussed later if active myeloma develops. CION's haematology team does not perform transplants but coordinates referral and access with qualified centres when one is needed.
How long is early treatment usually given?
It varies with the medicine and the study it is based on. Many approaches use a fixed period with regular review rather than lifelong treatment. Your haematologist will set out the planned length and the points at which it will be reviewed.
Should I get a second opinion?
It is reasonable, especially because this decision has no single right answer. Take all your reports, marrow results and scans. A second haematologist can confirm the risk group and talk through the options, which many families find reassuring either way.
What if I choose to watch and it progresses?
Close follow-up is designed to catch progression early, often before bones or kidneys are harmed. Treatment for active myeloma would then be planned. Keep every test date and report new bone pain, tiredness, infections or thirst straight away.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ), Health Professional Version
- National Cancer Institute — Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ), Patient Version
- American Cancer Society — Multiple Myeloma
- Leukemia & Lymphoma Society — Myeloma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Smouldering Myeloma: Between MGUS and MyelomaWhat smouldering myeloma is, before the decisionWhich MGUS Findings Prompt Urgent ActionSigns of progression that should not waitLiving With MGUS Without Living in FearCoping with the uncertainty of watchingBlood cancer guideThe wider picture of blood cancers
Talk to us
Weighing up treatment for smouldering myeloma?
Share your reports with us. Our haematology team will review your risk, talk through the options and help you reach a decision you are comfortable with.